Cargando…

Ceftazidime-avibactam

The increase in nosocomial infections by beta-lactamase-producing Gram-negative bacilli constitutes a therapeutic challenge. The combination of ceftazidime-avibactam offers a very interesting therapeutic option for nosocomial pneumonia caused by extended-spectrum beta-lactamase-producing Klebsiella...

Descripción completa

Detalles Bibliográficos
Autor principal:	Herrero, Francisco Sanz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedad Española de Quimioterapia 2022
Materias:	New Antimicrobial Alternatives in the Treatment of Pneumonia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106208/ https://www.ncbi.nlm.nih.gov/pubmed/35488824 http://dx.doi.org/10.37201/req/s01.09.2022

Ejemplares similares

Ceftolozane-tazobactam in nosocomial pneumonia
por: Candel, Francisco Javier, et al.
Publicado: (2022)

Ceftobiprole medocaril
por: Méndez, Raúl, et al.
Publicado: (2022)

New evidence in severe pneumonia: imipenem/ cilastatin/relebactam
por: Girón, Rosa Mª, et al.
Publicado: (2022)

New evidence in severe pneumonia: meropenemvaborbactam
por: Guillot, María Forteza, et al.
Publicado: (2022)

Ceftaroline in severe community-acquired pneumonia
por: Cilloniz, Catia, et al.
Publicado: (2022)

Cefiderocol
por: Soriano, María Cruz, et al.
Publicado: (2022)

Ceftazidime-avibactam
por: Matesanz, Mayra, et al.
Publicado: (2021)

Ceftazidime/avibactam for specified infections
Publicado: (2020)

Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children
por: Srivastava, Shashikant, et al.
Publicado: (2020)

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
por: Huang, Zeyu, et al.
Publicado: (2023)

Prevalence and correlates of treatment failure among Kenyan children hospitalised with severe community-acquired pneumonia: a prospective study of the clinical effectiveness of WHO pneumonia case management guidelines
por: Agweyu, Ambrose, et al.
Publicado: (2014)

Patient Detection of a Drug Dispensing Error by Use of Physician-Provided Drug Samples
por: Ashley, Elizabeth S Dodds, et al.
Publicado: (2002)

Science or Fiction: Use of Nesiritide as a First-Line Agent?
por: Noviasky, John A, et al.
Publicado: (2003)

Assessing the risk of stroke from neck manipulation: a systematic review
por: Haynes, M J, et al.
Publicado: (2012)

Assessment of food habits in children aged 6–12 years and the risk of caries
por: Doichinova, Liliya, et al.
Publicado: (2015)

Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies
por: Law, Arjun Datt, et al.
Publicado: (2018)

The effect of intracoronary infusion of bone marrow‐derived mononuclear cells on all‐cause mortality in acute myocardial infarction: rationale and design of the BAMI trial
por: Mathur, Anthony, et al.
Publicado: (2017)

Identification of a Novel Ceftazidime-Avibactam-Resistant KPC-2 Variant, KPC-123, in Citrobacter koseri Following Ceftazidime-Avibactam Treatment
por: Wang, Lin, et al.
Publicado: (2022)

Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam
por: Xiong, Luying, et al.
Publicado: (2022)

Treatment of Carbapenem-Resistant Enterobacteriaceae Infections with Ceftazidime-Avibactam
por: Rahmati, Elham, et al.
Publicado: (2017)

Ceftazidime/Avibactam Resistance in Carbapenemase-Producing Klebsiella pneumoniae
por: Cui, Qiaozhen, et al.
Publicado: (2023)

Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis
por: Li, Dan, et al.
Publicado: (2021)

Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in China
por: Cui, Xiaoyan, et al.
Publicado: (2020)

Selecting the dosage of ceftazidime–avibactam in the perfect storm of nosocomial pneumonia
por: Das, Shampa, et al.
Publicado: (2019)

In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae
por: Huang, Yanqin, et al.
Publicado: (2021)

Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
por: Jacobs, Jeremy, et al.
Publicado: (2020)

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa
por: Daikos, George L., et al.
Publicado: (2021)

Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
por: Mancuso, Alessandro, et al.
Publicado: (2023)

A Phase 2a dose‐escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS‐986231 in hospitalized patients with heart failure with reduced ejection fraction
por: Tita, Cristina, et al.
Publicado: (2017)

Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
por: Fiore, Marco, et al.
Publicado: (2020)

Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates
por: Montero, María M., et al.
Publicado: (2021)

In vitro activity of cefiderocol against comparators (ceftazidime-avibactam, ceftazidime-avibactam/ aztreonam combination, and colistin) against clinical isolates of meropenem-resistant Klebsiella pneumoniae from India
por: Borde, Kalyani, et al.
Publicado: (2023)

In Vitro Activity Comparison of Ceftazidime–Avibactam and Aztreonam–Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China
por: Yu, Wei, et al.
Publicado: (2021)

In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa
por: Gill, Christian M, et al.
Publicado: (2022)

Investigation of ceftazidime-avibactam susceptibility in clinical isolates of gram-negative bacteria
por: DUMLU, Rıdvan, et al.
Publicado: (2022)

Effect of In Vitro Testing Parameters on Ceftazidime-Avibactam Minimum Inhibitory Concentrations
por: Keepers, Tiffany R., et al.
Publicado: (2015)

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
por: Goodlet, Kellie J, et al.
Publicado: (2016)

Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae
por: Alraddadi, Basem M., et al.
Publicado: (2019)

Interactions between Avibactam and Ceftazidime-Hydrolyzing Class D β-Lactamases
por: Frère, Jean-Marie, et al.
Publicado: (2020)

Ceftazidime–Avibactam versus Meropenem for the Treatment of Complicated Intra-Abdominal Infections
por: Tan, Che-Kim, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1dbiljj6ocj6q9o2clb9mv69ub